Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of HealthEquity, Inc. (NASDAQ:HQY)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of HealthEquity, Inc. (NASDAQ:HQY). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in HealthEquity stock on May 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.
• Sold $15,001 – $50,000 in shares of Workday (NASDAQ:WDAY) on 5/29/2026.

HealthEquity Price Performance

Shares of HQY traded up $0.50 on Wednesday, reaching $89.73. The stock had a trading volume of 663,235 shares, compared to its average volume of 1,007,371. The firm has a market capitalization of $7.50 billion, a PE ratio of 33.61, a PEG ratio of 1.48 and a beta of 0.21. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. The firm has a 50-day moving average of $84.27 and a 200 day moving average of $86.03. HealthEquity, Inc. has a twelve month low of $72.76 and a twelve month high of $107.66.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Thursday, May 28th. The company reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. The business had revenue of $354.64 million for the quarter, compared to analysts’ expectations of $352.02 million. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The company’s quarterly revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Sell-side analysts expect that HealthEquity, Inc. will post 3.92 EPS for the current year.

Institutional Investors Weigh In On HealthEquity

A number of large investors have recently bought and sold shares of HQY. William Blair Investment Management LLC acquired a new stake in HealthEquity during the 4th quarter valued at $169,956,000. Norges Bank purchased a new position in shares of HealthEquity during the 4th quarter worth $66,927,000. AQR Capital Management LLC lifted its stake in shares of HealthEquity by 148.5% during the 2nd quarter. AQR Capital Management LLC now owns 1,107,448 shares of the company’s stock worth $116,016,000 after purchasing an additional 661,795 shares during the period. Wasatch Advisors LP lifted its stake in shares of HealthEquity by 9.3% during the 1st quarter. Wasatch Advisors LP now owns 7,202,934 shares of the company’s stock worth $601,949,000 after purchasing an additional 613,288 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of HealthEquity by 151.5% during the 4th quarter. Millennium Management LLC now owns 951,563 shares of the company’s stock worth $87,173,000 after purchasing an additional 573,283 shares during the period. Institutional investors and hedge funds own 99.55% of the company’s stock.

Analysts Set New Price Targets

HQY has been the topic of a number of research reports. BMO Capital Markets upgraded HealthEquity from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $85.00 to $105.00 in a report on Thursday, April 9th. JPMorgan Chase & Co. lowered their target price on HealthEquity from $129.00 to $123.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft increased their target price on HealthEquity from $120.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, March 19th. Raymond James Financial set a $100.00 target price on HealthEquity in a report on Tuesday, February 17th. Finally, UBS Group set a $110.00 target price on HealthEquity in a report on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, HealthEquity currently has an average rating of “Moderate Buy” and an average price target of $110.57.

Insiders Place Their Bets

In other HealthEquity news, EVP Delano Ladd sold 7,500 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total transaction of $675,000.00. Following the transaction, the executive vice president owned 91,141 shares of the company’s stock, valued at $8,202,690. This represents a 7.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gayle Furgurson Wellborn sold 2,439 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $219,510.00. Following the transaction, the director directly owned 19,733 shares in the company, valued at approximately $1,775,970. This represents a 11.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,081 shares of company stock valued at $1,193,000 in the last quarter. 1.60% of the stock is currently owned by company insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.